aussi disponible en français
September 10, 2012
For immediate release
Delivra Inc. to begin research on PEI with support from the Government of Canada
Innovation and Advanced Learning
“Our Government continues to focus on our top priorities of jobs, growth and long-term prosperity, and investing in innovative companies like Delivra Inc. is an effective way to meet these goals,” said Minister Goodyear, on behalf of the Honourable Bernard Valcourt, Associate Minister of National Defense and Minister of State (Atlantic Canada Opportunities Agency) (La Francophonie). "The Government of Canada’s investment will help Delivra Inc. to establish its presence in Prince Edward Island, boost national innovation and break into major global markets, all of which will have a positive economic impact on the Atlantic Canadian economy.”
Delivra™ is a unique base compound that acts as an alternative drug delivery system. It safely penetrates deep through the skin to reach joints, muscles, and other tissues, and delivers active ingredients to areas that other topicals cannot reach. The technology holds tremendous potential for different applications and there is nothing like it in the healthcare field today. Delivra™ was developed by Dr. Joseph Gabriele, a Canadian university professor and molecular pharmacologist who discovered its properties while assisting his wife in dealing with chronic pain.
The Government of Canada, through ACOA’s Business Development Program, has invested a total of $220,000 to help Delivra Inc. open their new research facility on Prince Edward Island. This investment includes the purchasing of the new equipment, which is necessary for Delivra to conduct their research.
“This vital funding will help us investigate new opportunities to combine Delivra™ with other medications that can only be taken orally or through injectibles today,” said Dr. Gabriele who is also president and chief scientific officer of Delivra Inc. “As a result of the government’s investment into Delivra Inc., many Canadians will one day be able to take their current medications in a safer topical format – getting the same benefit, but with fewer side effects.”